The Impact Of Biogen Alzheimer's Drug FDA Approval

<p>The FDA has approved Biogen’s (BIIB) Alzheimer’s drug. Brad Loncar, CEO of Loncar Investments, talks about the impact of the Biogen drug approval as well as the recent activity in the health care sector. He also discusses how Biogen’s treatment compares to others in the pipeline and what he believes is the next catalyst in the health care sector. Tune in to find out more.</p><p><br></p>